TYSABRI er indiceret som en monoterapeutisk sygdomsmodificerende behandling hos patienter med relapsing- remitting multipel sklerose for at forhindre attakker og for at forsinke progression af handikapudvikling.
TYSABRI is indicated as a single disease modifying therapy in relapsing remitting multiple sclerosis to prevent relapses and delay progression of disability.